Lyell Immunopharma (LYEL) Non-Current Assets (2020 - 2026)

Lyell Immunopharma has reported Non-Current Assets for 7 years, with the latest figure at $83.3 million in Q1 2026.

• Quarterly Non-Current Assets fell 30.92% year-over-year to $83.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $345.4 million (down 37.8% YoY) and the FY2025 annual result came in at $79.1 million, down 28.9% from the prior year.
• Non-Current Assets advanced to $83.3 million in Q1 2026 per LYEL's latest filing, from $79.1 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $446.4 million in Q1 2022 and troughed at $79.1 million in Q4 2025.
• A 5-year average of $197.3 million and a median of $169.2 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets decreased 10.16% in 2022, then sank 52.85% in 2025.
• Over 5 years, Non-Current Assets stood at $286.3 million in 2022, then tumbled by 31.76% to $195.3 million in 2023, then plunged by 43.04% to $111.3 million in 2024, then retreated by 28.9% to $79.1 million in 2025, then advanced by 5.32% to $83.3 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $83.3 million, $79.1 million, and $79.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.